AGT‑160 is an investigational brain-penetrating anti-amyloid antibody (AAA) for the treatment of Alzheimer’s disease (AD). AD is caused by deposition of amyloid plaque in the brain, and administration of an AAA can break down plaque. However, the plaque in the brain is behind the BBB, and an AAA cannot penetrate the brain without disrupting the BBB. Additionally, the current class of AAA biologics can cause large and sustained elevations in blood concentrations of toxic molecules called amyloid peptides.

AGT-160’s ability to cross the BBB allows AGT-160 to break down plaque without causing toxic side effects associated with high blood levels of amyloid peptide.

In preclinical studies, AGT-160 was rapidly removed from the blood. Additionally, in a mouse model of AD, IV injection of AGT-160 caused a 40% decrease in the brain concentration of ABeta amyloid peptide, but caused no elevation in ABeta amyloid peptide in the blood, and caused no cerebral micro-hemorrhage.1

Preclinical validation studies of AGT-160 are ongoing in AD.


Reference:

1 Zhang W, et al. Blood-brain barrier transport of amyloid beta peptides in efflux pump knock-out animals evaluated by in vivo optical imaging. Fluids Barriers CNS. 2013;10:13